Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
GRAIL, Inc. (Nasdaq: GRAL) is a healthcare diagnostics company whose mission is to detect cancer early, when it can be cured. The company’s news flow centers on developments related to its multi-cancer early detection (MCED) blood test, Galleri, and the targeted methylation-based platform that underpins it. GRAIL regularly reports on clinical study results, commercial collaborations, capital-raising activities, and investor events, giving readers insight into how its MCED strategy is progressing.
News updates often highlight data from large clinical studies such as PATHFINDER 2 and SYMPLIFY, where GRAIL describes Galleri’s performance when added to standard-of-care screening or used in symptomatic populations. These releases provide details on cancer detection rates, positive predictive value, specificity, cancer signal origin accuracy, and safety outcomes, as well as how Galleri may detect cancers that lack recommended screening options.
Investors and healthcare observers can also find announcements about financial results, private placements, and equity distribution arrangements, which GRAIL describes as supporting its commercial and reimbursement efforts. Additional coverage includes strategic collaborations, such as agreements with Medcan and Manulife Canada for access to Galleri, and a planned collaboration with Samsung-related entities to commercialize the test in certain Asian markets, subject to regulatory and contractual conditions.
This news page aggregates these company-issued updates so readers can follow GRAIL’s reported clinical evidence, commercial partnerships, financing transactions, and conference presentations over time.
Superpower (partnering with GRAIL, Nasdaq: GRAL) announced a strategic partnership on April 1, 2026 to offer the Galleri multi-cancer early detection test through Superpower's preventative health platform.
Galleri detects signals from more than 50 cancer types, PATHFINDER 2 showed detection rose more than seven-fold, and over half of cancers found were stage I or II. Testing is available via Quest's ~3,000+ patient access points, requires a prescription, and is recommended for adults at elevated risk (eg, aged 50+).
GRAIL (Nasdaq: GRAL) announced that CEO Bob Ragusa will retire effective June 1, 2026, and that President Josh Ofman, MD, MSHS, will succeed him and join the Board immediately. Ragusa will remain on the Board until June 1, 2026, and serve as a senior advisor through March 2027.
The Board described Ofman's background in clinical medicine, health policy, reimbursement, and leadership of the Galleri evidence program as key to continuity and advancing regulatory and commercial progress.
GRAIL (Nasdaq: GRAL) granted inducement equity awards of restricted stock units covering an aggregate of 19,500 shares to 20 newly hired non-executive employees under its Inducement Equity Incentive Plan dated March 2, 2026.
The RSUs vest over approximately four years, with 25% vesting Feb. 28, 2027 and the remainder vesting on each annual anniversary thereafter, subject to continued employment.
GRAIL (Nasdaq: GRAL) said company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Mar. 3, 2026 at 10:30 a.m. ET.
Live and replay webcasts will be available via the company's investor relations website and archived for at least 30 days after the event.
GRAIL (Nasdaq: GRAL) reported Q4 2025 revenue of $43.6M (14% YoY) and full‑year revenue of $147.2M (17% YoY). U.S. Galleri revenue was $136.8M (26% YoY). Net loss was $99.2M for Q4 and $408.4M for 2025.
The company completed its PMA submission to FDA, reported NHS‑Galleri topline results (reduced Stage IV but did not meet primary endpoint), finished PATHFINDER 2 analysis, and held $904.4M cash, providing runway into 2030.
GRAIL (Nasdaq: GRAL) reported topline results from the randomized NHS-Galleri trial in 142,000 participants aged 50–77 over three years. The primary combined Stage III–IV reduction endpoint was not met, though a favorable trend appeared. Key findings: a four-fold higher cancer detection rate, >20% reduction in Stage IV diagnoses in rounds 2–3 for 12 deadly cancers, increased Stage I–II detection, fewer emergency presentations, and consistent test performance metrics.
GRAIL (Nasdaq: GRAL) will report fourth quarter and full year 2025 financial results after market close on Thursday, Feb. 19, 2026.
Management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and business progress. According to the company, a live webcast and recorded replay will be available at the investor relations site and open to all.
GRAIL (Nasdaq: GRAL) submitted the final module of a Premarket Approval (PMA) application to the U.S. FDA on Jan 29, 2026 for the Galleri multi-cancer early detection test.
The filing cites performance and safety data from 25,490 PATHFINDER 2 participants and first-year data from the randomized NHS-Galleri trial, plus a bridging analysis to the PMA test version. Galleri received Breakthrough Device designation in 2018.
GRAIL (Nasdaq: GRAL) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12, 2026 at 7:30 a.m. PT. Live and replay webcasts will be available in the investor relations section at investors.grail.com. The webcast will be archived and available for replay for at least 30 days after the event.
GRAIL (Nasdaq: GRAL) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to recent hires on Dec. 1, 2025. The company issued restricted stock units totaling 21,570 shares to 21 non-executive employees under its Inducement Equity Incentive Plan as an employment inducement.
The RSUs vest over an approximately four-year schedule, with 25% vesting on Nov. 30, 2026 and the remainder vesting on each one-year anniversary thereafter, subject to continued employment with GRAIL or its successor/subsidiary.